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Poster Session-I 39status (P5 0.1); and extra nodal involvement (p5 0.4).We identified
an inverse correlation between day 15 IL-15 and day 15 NK cell re-
covery (r 5 20.5, p\ 0.0001). Patients with a day15 IL-15 # 9.5
pg/ml experienced higher numbers of NK cells compared with those
with a day 15 IL-15. 9.5 pg/ml [median 142 cells/ml (range: 10–416
cells/ml) versus median 57.5 cells/ml (range: 28–999 cells/ml), p\
0.001, respectively]. Using logistic regression models, univariately
day 15 IL-15 was a predictor for NK cell recovery (p\0.0003) and
multivariately day 15 IL-15 remained a predictor for NK cell recov-
ery (p\0.0004). To our knowledge, this is the first study showing an
associationbetweenday 15 IL-15 andNKcell recovery inASCT.We
showed an inverse relationship between day 15 IL-15 and NK cell
numbers consistent with a homeostatic association. The data pre-
sented here suggest that day 15 NK cell recovery might be driven
by the cytokine milieu post-ASCT.95
IMMUNOTHERAPY WITH RITUXIMAB (RITUXAN)/INTERLEUKIN 2 (IL-2)
FOLLOWING AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANS-
PLANT (ASCT) AS TREATMENT FOR CD20 POSITIVE NON-HODGKIN’S
LYMPHOMA
Holmberg, L.A.1,2,3, Maloney, D.G.1,2,3, Bensinger, W.I.1,2,3 1Fred
Hutchinson Cancer Research Center (FHCRC), Seattle, WA; 2University
of Washington School of Medicine, Seattle, WA; 3Puget Sound Oncology
Consortium, Seattle, WA
Relapse of NHL is a problem after ASCT. Early after ASCT, the
immune system is not as active, which can impair the ability to erad-
icate residual disease. The addition of immunotherapy may decrease
the incidence of relapse and prolong survival. In a phase I/II trial at
FHCRC, the immune-modulator IL-2 increased NK and LAK ac-
tivity in vitro. Since Rituxan lyses CD201 cells by ADCC, adding
Rituxan to IL-2 should boost its effectiveness. Twenty patients
with CD201NHL received ASCT followed by Rituxan/IL-2 ther-
apy. The pathology at ASCT included: follicular small/large cleaved
(n5 2), diffuse large/T cell rich B cell (n5 8), mantle cell (n5 4) and
transformed from indolent to diffuse (n 5 6). The disease status at
ASCT was refractory (n 5 8), relapse 1 (PR) (n 5 1), remission 1
(n 5 3), remission 2 (n5 6) and relapse/untreated (n 5 1). Previous
Rituxan use was (n 5 9). The median age of patients was 46 years
(range 31–70). The median time to initiation of therapy was 79
days post ASCT (range 49–100). The treatment schema was: IL-2
0.6  106 IU/m2/day sc times 12 weeks, followed by 1.4  106 IU/
m2 sc 3 times/week for an additional 12 weeks (total of 24 weeks of
IL-2 therapy). Rituxan was given iv at 375 mg/m2 for a total of 4
doses: beginning one day prior to starting IL-2, then between days
25–30, 50–55 and 75–80 post beginning IL-2. NCI Common Tox-
icity Criteria were used to evaluate adverse events. Most common
grade 3/4 toxicities were neutropenia (n 5 9), pneumonia (n 5 2)
at 7–8 weeks of therapy, hypothyroidism (n 5 1), hypokalemia
(n 5 1) and pulmonary dysfunction (decreased DLCO) (n 5 1) at
5 weeks of therapy. Neutropenia responded to G-CSF. There
were 11 infections: pneumonia (influenza, n5 1, and pneumococcus
strept, n 5 1), oral thrush (n 5 2), herpes simplex (n 5 1), urinary
tract (n5 1), zoster (n5 1) and upper respiratory (n5 4).Most com-
mon side effects were fatigue, erythema/induration/discomfort at
IL-2 injection sites and flu-like symptoms. Seven patients stopped
therapy due to subdural hematoma/progression of NHL (n 5 1),
pneumonia (n 5 2), decreased DLCO (n 5 1) or at own/physician’s
choice without grade 3/4 toxicity at 9, 13, 14.5 weeks after complet-
ing Rituxan (n5 3). With a median follow-up of 76.5 months (range
43–93), 18 patients (90%) are alive, 17 patients (85%) are alive inCR.
Two patients died of relapsed disease. The combination of IL-2/Rit-
uxan after ASCT continues to show a high and durable response rate
in CD201 NHL patients.96
AUTOLOGOUS HEMATOPOEITIC STEM CELL TRANSPLANTATION (HSCT)
IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) IN FIRST OR SEC-
OND REMISSION
Naqvi, H., John, V., Devoe, C., Kiner, B., Kolitz, J., Allen, S.,
Gissinger, D., Cannon, M., Fitzgerald, E., Klocke, J., Bayer, R.-L. North
Shore University Hospital, Manhasset, NYWe report 40 patients (pts) with AMLwho underwent autologous
HSCT in first (CR1) or second (CR2) remission from 2002 to 2007.
Twenty one were male and nineteen were female with a mean age of
52.8 (range 35–66) years. Patients enrolled in clinical trials are not
included in this analysis. Using CALGB (Byrd) criteria, 6 had favor-
able cytogenetic risk (all in CR2), 26 had intermediate risk, including
22 with normal karyotypes (20 in CR1 and 2 in CR2), and 8 had un-
favorable cytogenetics (7 in CR1 and 1 in CR2), including two pa-
tients with t(9;22). One pt had Ph1 AML and one CML with
myeloid blast crisis. One patient had AML transformed frommyelo-
dysplastic syndrome (MDS). Four patients had AMLwith multi-lin-
eage dysplasia (MLD). Nine patients were in CR2. Thirty-five
patients had intensification / mobilization with high dose VP16/
ARAC, four with high dose ARAC and one patient had a bone mar-
row harvest. Thirty-six patients received Busulfan (0.8mg/kg x 16
doses) and VP-16 (60mg/kg) as their preparative regimen. Four re-
ceived Busulfan (0.8 mg/kg x 16 doses) and Cytoxan (120 mg/kg).
One hundred day transplant related mortality was 2.5%.Mean over-
all survival was 20.9 months. Mean disease free survival was 36.7
months with a range of 10–76 months. One year overall survival
was 63%, with a one year disease free survival of 40%. Four of six
pts with favorable cytogenetics are alive in CR more than 24 months
after autologous transplant. Two patients with t(9;22) are on imati-
nib maintenance in CR 12 and 42 months post transplant. One pa-
tient with APL developed a secondary MDS with a monosomy 7.
No patients with prior MDS or MLD were alive after 12 months.
Five patients who relapsed after autologous HSCT went on to re-
ceive reduced intensity allogeneic transplantation with a 100 day
mortality of 0%. We conclude that autologous HSCT should be
considered an effective and safe post-remission consolidation ther-
apy for pts with intermediate risk AML in CR1 and for pts with fa-
vorable cytogenetics in CR2. Patients with MLD and prior MDS
do poorly. Prior autologous HSCT does not increase the 100 day
mortality with reduced intensity allogeneic transplantation. Further
studies are necessary, continuing to focus on risk-adapted therapy
and assessing quality of life endpoints.97
PHYSICAL PERFORMANCE FACTORS AND OVERALL SURVIVAL AFTER AU-
TOLOGOUS AND ALLOGENEIC BMT
Hahn, T.1, Smiley, S.L.1, Tan, W.2, Wilding, G.2, Thomas, J.1,
Fassl, K.1, Wright, C.1, Battiwalla, M.1, McCarthy, P.L.1 1Roswell
Park Cancer Institute, Buffalo, NY; 2Roswell Park Cancer Institute, Buf-
falo, NY
Many tests are used to determine patient physical fitness for
blood and marrow transplant (BMT). BMT patients usually re-
ceive prior toxic therapies that result in deconditioning pre-
BMT. One measure of physical fitness is the ability to reach
a target heart rate without a significant decrease in oxygen satu-
ration (O2sat) during exercise. We retrospectively analyzed 183
consecutive first adult ($18 years) autologous (n 5 95) or alloge-
neic (n 5 88) BMT pts treated from 7/05 to 4/08 to analyze
overall survival (OS) in relation to a pre-BMT physical therapy
evaluation, along with standard cardiac and pulmonary function
tests. The physical therapy evaluation included Karnofsky perfor-
mance score (KPS), resting and post-exercise heart rate (HR) and
O2sat, ability to reach target HR and ability to complete an ex-
ercise test consisting of 50 step-ups or walking on a treadmill.
Median age was 53 yrs (range 18–71), male 61%, White 93%,
leukemia (n 5 65), lymphoma (n 5 68), myeloma (n 5 24), he-
matologic disorders (n 5 23), and solid tumors (n 5 3), donors
were autologous (n 5 95), related (n 5 37), or unrelated (n 5
51). Median follow-up in survivors was 1 yr (range 0.1–2.9).
162 (89%) were able to complete the exercise test; reasons for
not completing the test included fatigue and rapid heart rate.
37% of autologous and 21% of allogeneic BMT patients who
completed the exercise test reached their target HR. Medians
(ranges) were: resting HR 87.5 (56–150) and O2sat 98 (89–
100), post-exercise HR 126.5 (72–186) and O2sat 98 (88–100),
left ventricular ejection fraction (LVEF) 61 (50–80), corrected
carbon monoxide diffusing capacity (DLCOcorr) 80 (35–126),
forced expiratory volume in one second (FEV1) 95 (35–146).
Multivariate analysis used a Cox proportional hazards model
with backward elimination with the following potential
40 Poster Session-Ipredicators of OS: age, gender, diagnosis, KPS, stem cell source,
LVEF, resting HR and O2sat, reaching target HR, DLCOcorr
and FEV1. For allogeneic BMT, multivariate analysis demon-
strated age\40 years (RR 5 0.37, p 5 0.03) and higher FEV1
(RR 5 0.98, p 5 0.02) had a decreased risk and KPS#80 (RR
5 3.19, p 5 0.01) had increased risk of death. For autologous
BMT, multivariate analysis demonstrated significantly decreased
risk of death for higher baseline HR (RR 5 0.95, p 5 0.002),
baseline O2sat (RR 5 0.69, p 5 0.01), LVEF (RR 5 0.91, p
5 0.04) and DLCOcorr (RR 5 0.97, p 5 0.02). Early OS
may be predicted using simple measures of cardiac, pulmonary
and exercise functions pre-BMT.98
PRE-TRANSPLANT CLONAL CYTOGENETIC ABNORMALITIES IN STEM
CELLS USED FOR AUTOLOGOUS STEM CELL TRANSPLANT FOR RELAPSED
NON-HODGKIN LYMPHOMA IS A PREDICTOR OF RELAPSE
Rojas, A.M., De Vos, S., Pinter-Brown, L., Paquette, R., Schiller, S.,
Territo, M.C. UCLA, Los Angeles, CA
Autologous stem cell transplant is used for chemotherapy sensitive
relapsed Non-Hodgkin Lymphoma (NHL). Patients who receive an
autologous stem cell transplant after high dose chemotherapy for re-
lapsed NHL have significantly superior survival compared to those
receiving conventional chemotherapy. Relapsed patients who
achieve a second remission are treated with myeloablative chemo-
therapy followed by autologous stem cell transplant. These patients
can achieve 5-year event free survival close to 50% and 5-year overall
survival of greater than 50%. We performed a retrospective analysis
of our center’s transplant data and reviewed pre-transplant cytoge-
netic analysis on the patient’s collected stem cells. 259 patients un-
derwent autologous stem cell transplant from 1998 through 2007
for relapsed NHL. Cytogenetic evaluations of the patient’s pre-
transplant stem cells had been done to look for evidence of MDS
or characteristics of their lymphoma. Clonal cytogenetic abnormal-
ities were found in 12 of the 259 patients. Two of these patients died
within 45 days of transplant without evidence of relapse. One from
infection and a second from non-treatment related causes. Nine of
the remaining 11 (81%) patients with clonal cytogenetic abnormal-
ities have relapsed and died. All patients relapsed with their original
lymphoma. The cytogenetic abnormalities were varied. Out of the 9
relapses, 3 had cytogenetic abnormalities in the stem cells that are as-
sociated with lymphoma, 2 that are associated with AML, 1 that is
associated with MDS, and 2 were abnormalities whose significance
was unknown. In one patient cytogenetic changes of the original
lymphoma were identified. The patients that had clonal cytogenetic
abnormalities in their collected stem cells had an 81% relapse rate as
opposed to 30% in the patients whose stem cells had a normal kar-
yotype. Our findings show that cytogenetic changes in the collected
stem cells are associated with a higher rate of lymphoma relapse.99
AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) WITH A PCR-NEG-
ATIVE GRAFT WAS ASSOCIATED WITH A FAVORABLE OUTCOME FOR
CORE-BINDING-FACTOR ACUTE MYELOID LEUKEMIA (CBF-AML)
Nakasone, H.1,2, Izutsu, K.1, Wakita, S.3, Yamaguchi, H.3, Muramatsu-
Kida, M.1, Usuki, K.1 1Kanto Medical Center NTT EC, Shinagawa-ku,
Tokyo, Japan; 2SaitamaMedical Center, Jichi Medical University, Grad-
uate School; 3Nippon Medical School
Although core binding factor acute myeloid leukemia (CBF-
AML) is generally considered to be a low-risk form of AML, the sur-
vival rate is still 50–60%. To evaluate the effectiveness of autologous
stem cell transplantation (ASCT) with a PCR-negative graft, we an-
alyzed a series of consecutive CBF-AML patients. Between 1997 and
2006, 18 patients aged less than 60 years were referred under a diag-
nosis of CBF-AML. Peripheral blood stem cells (PBSC) were col-
lected after a second or further course of post-remission therapy.
When more than 2.0 106/kg CD34-positive cells with minimal re-
sidual disease (MRD) undetectable by nested PCR had been col-
lected, ASCT was performed with busulfan, etoposide and
cytarabine combined with granulocyte colony-stimulating factor.
Event-free survival (EFS) and complications of ASCT were then as-sessed. Fourteen of the 18 patients received ASCT. The median ob-
servation period was 4.4 years. The 5-year EFS was 93% for ASCT
patients, despite the presence of adverse factors. In 8 of 10 patients
who had detectable MRD in the bone marrow before ASCT,
MRD became undetectable after ASCT. Neutrophils recovered
promptly within 2 weeks, but platelets recovered relatively slowly.
Half of the patients suffered from varicella zoster virus infection. Al-
though one case of myelodysplastic syndrome occurred, there was no
case of relapse. ASCTwith a PCR-negative graft was associated with
excellent EFS. For patients with CBF-AML, especially with adverse
factors or remnant MRD in the bone marrow, this strategy is the
treatment of choice.100
FEBRILE REACTIONS OCCURRING WITH SECOND CYCLE OF HIGH DOSE
MELPHALAN AND STEM CELL TRANSPLANTATION IN PATIENTS WITH
AL AMYLOIDOSIS: A ‘‘MELPHALAN RECALL’’ REACTION
Rosenzweig, M.A.1, Seldin, D.C.1, Remick, D.3, Skinner, M.2,
Quillen, K.1, Oran, B.2, Finn, K.T.1, Sanchorawala, V.1 1Boston Univer-
sityMedical Center, Boston,MA; 2Boston University Medical Center, Bos-
ton, MA; 3Boston University Medical Center, Boston, MA
Systemic AL amyloidosis is a clonal plasma cell disease character-
ized by the wide spread deposition of amyloid fibrils into tissues and
organs. Treatment for this disease is directed towards reducing the
production of amyloidogenic monoclonal light chains by attacking
the underlying plasma cell dyscrasia. Aggressive treatment with
high dose intravenous melphalan followed by autologous stem cell
transplantation (HDM/SCT) is effective in inducing hematologic
and clinical remissions and in extending survival. Tandem cycles of
HDM/SCT have been shown to increase hematologic complete re-
sponse (HCR) rates in patients with AL amyloidosis. Between April
1994 and July 2008, 57 patients with AL amyloidosis at Boston Uni-
versity medical center were treated with a second cycle of HDM/
SCT after failing to achieve a HCR following a first transplantation.
Eleven of 57 patients (19%) treated with tandem transplantation de-
veloped a high fever 12–24 hours following melphalan administra-
tion. Other clinical features noted in some of the patients include
hypotension, acute renal failure, and skin rash. Among the 11
patients described, there were 7 men and 4 women. The average
age was 53.5 years (range 41–60). The average peak temperature of
the 11 patients was 39.1oC (range, 38.1–39.4oC). All patients
experienced resolution of fever within 24–48 hours. Six of the 11 pa-
tients developed a rash and 5 developed hypotension that was re-
sponsive to intravenous fluids or pressors when indicated. Two of
the patients developed acute renal failure that improved following
resolution of the fever. In all 11 patients, workup for an infectious
etiology of fever was negative. One of the 11 patients described,
had cytokine measurements before, during and after the febrile
reaction. The concentration of several pro-inflammatory as well as
anti-inflammatory cytokines increased significantly. IL-6, a classic
endogenous, pyrogenic cytokine, increased 10 fold with this reaction
demonstrating a clear physiologic response correlating with the clin-
ical findings. We conclude that an unusual febrile reaction mediated
by pyrogenic cytokines can occur in patients with AL amyloidosis ex-
posed to a second cycle of high dose melphalan. While this reaction
has not been observed in patients with multiple myeloma treated in
similar fashion, clinicians should be aware of this phenomenon we
have termed a ‘‘melphalan recall’’ reaction in patients with AL amy-
loidosis treated with tandem cycles of HDM/SCT.101
CLINICAL PATHWAYS AND STANDARD OPERATING PROCEDURES: ES-
SENTIAL TOOLS FOR OUTPATIENT STEM CELL TRANSPLANT PROGRAMS
TREATING PATIENTS WITH AL AMYLOIDOSIS
Finn, K.T., Fennessey, S., Yanarella, L., Antonelli, C., Shelton, A.,
Daniel, S., Skinner, M., Seldin, D., Quillen, K., Sanchorawala, V. Boston
University Medical Center, Boston, MA
Clinical pathways (CPs) and standard operating procedures
(SOPs) are necessary for treating AL patients with high-dose mel-
phalan and stem cell transplantation (HDM/SCT) in the outpatient
setting. AL is a plasma cell dyscrasia in which abnormal proteins
